3 results
Not approvedWill not start
Objective: To assess whether angiotensin receptor blocker (ARB) use is beneficial in the early phase of the disease, to prevent lung oedema and damage in high risk patients with a proven COVID-19 infection.
Approved WMORecruiting
The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B).
Approved WMORecruiting
• to assess the efficacy of the sequential combination strategy of front-line afatinib-chemo, followed by a treatment with osimertinib-chemo in those patients that develop a T790M mutation as a mechanism of resistance.